Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)

Summary

This study aims to compare the effectiveness and safety regarding treatment with standard anticoagulant only or adding antiplatelet to anticoagulant in patients with non-valvular atrial fibrillation and significant atherosclerosis including extracranial, intracranial, coronary or peripheral artery.

Conditions

• Acute Ischemic Stroke
• Atrial Fibrillation
• Extracranial Atherosclerosis
• Intracranial Atherosclerosis
• Coronary Artery Atherosclerosis
• Peripheral Artery Stenosis
• Anticoagulant
• Antiplatelet

Interventions

DRUG

Edoxaban Monotherapy

when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.

Sponsors & Collaborators

• Samsung Medical Center

  collaborator OTHER

• Myongji Hospital

  collaborator OTHER

• Ewha Womans University

  collaborator OTHER

• Chonbuk National University

  collaborator OTHER

• Pusan National University Hospital

  collaborator OTHER

• Korea University Ansan Hospital

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Korea University Guro Hospital

  collaborator OTHER

• Chungnam National University Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Dongtan Sacred Heart Hospital

  collaborator OTHER

• Eulji University Hospital

  collaborator OTHER

• Asan Medical Center

  lead OTHER

Principal Investigators

• Sun U. Kwon, MD, PhD · Asan Medical Center

Eligibility

Min Age

20 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-10-08

Primary Completion

2025-06-27

Completion

2026-06-27

FDA Drug

Yes

Countries

• South Korea

Study Locations